Chalasani Bio-Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 12 Year, 27 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 M
as on 11-12-2024
- Revenue 40.09%
(FY 2022)
- Profit -15.82%
(FY 2022)
- Ebitda -18.30%
(FY 2022)
- Net Worth 1.07%
(FY 2022)
- Total Assets -9.29%
(FY 2022)
About Chalasani Bio-Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.20 M.
Vijaya Chalasani and Saileesh Chalasani serve as directors at the Company.
- CIN/LLPIN
U24232AP2012PTC084422
- Company No.
084422
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Chalasani Bio-Pharma Private Limited offer?
Chalasani Bio-Pharma Private Limited offers a wide range of products and services, including Emergency Services, Medical Consultancy Services, Hospitals.
Who are the key members and board of directors at Chalasani Bio-Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijaya Chalasani  | Director | 26-Nov-2012 | Current |
| Saileesh Chalasani | Director | 28-Jan-2015 | Current |
Financial Performance of Chalasani Bio-Pharma.
Chalasani Bio-Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 40.09% increase. The company also saw a substantial fall in profitability, with a 15.82% decrease in profit. The company's net worth moved up by a moderate rise of 1.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chalasani Bio-Pharma?
In 2021, Chalasani Bio-Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Chalasani Hospitals Private LimitedActive 14 years 7 monthsVijaya Chalasani and Saileesh Chalasani are mutual person
- Radiance Medispas Private LimitedActive 14 years 3 months
Vijaya Chalasani and Saileesh Chalasani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Nov 2022 | ₹1.20 M | Open |
How Many Employees Work at Chalasani Bio-Pharma?
Unlock and access historical data on people associated with Chalasani Bio-Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chalasani Bio-Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chalasani Bio-Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
